Last reviewed · How we verify
Lactobacillus reuteri CR20
Lactobacillus reuteri CR20 is a Biologic drug developed by Universidad Complutense de Madrid. It is currently in Phase 2 development.
At a glance
| Generic name | Lactobacillus reuteri CR20 |
|---|---|
| Sponsor | Universidad Complutense de Madrid |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lactobacillus reuteri CR20 CI brief — competitive landscape report
- Lactobacillus reuteri CR20 updates RSS · CI watch RSS
- Universidad Complutense de Madrid portfolio CI
Frequently asked questions about Lactobacillus reuteri CR20
What is Lactobacillus reuteri CR20?
Lactobacillus reuteri CR20 is a Biologic drug developed by Universidad Complutense de Madrid.
Who makes Lactobacillus reuteri CR20?
Lactobacillus reuteri CR20 is developed by Universidad Complutense de Madrid (see full Universidad Complutense de Madrid pipeline at /company/universidad-complutense-de-madrid).
What development phase is Lactobacillus reuteri CR20 in?
Lactobacillus reuteri CR20 is in Phase 2.